Biogen (BIIB) PT Lowered to $240 at RBC Capital
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $220.83 -1.64%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 7 | New: 5
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 7 | New: 5
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams lowered the price target on Biogen (NASDAQ: BIIB) to $240.00 (from $242.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Biogen (BIIB) PT Raised to $245 at Piper Sandler
- Mama’s Creations (MAMA) PT Lowered to $22 at DA Davidson Following Q2 Beat
- Six Flags Entertainment (FUN) PT Lowered to $27 at UBS, Estimates Revised
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
